SCHEMBL190878

SCHEMBL190878

Cc1csc(Nc2cc(Sc3cccc(Cl)c3Cl)ccn2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 10/20 0.42
RAB9A P51151 9/20 0.42
MEN1 O00255 9/20 0.42
NPC1 O15118 9/20 0.42
CASP3 P42574 2/20 0.41
SENP8 Q96LD8 2/20 0.41
SENP7 Q9BQF6 2/20 0.41
SENP6 Q9GZR1 2/20 0.41
KCNN1 Q92952 1/20 0.41
KCNN2 Q9H2S1 1/20 0.41
KCNN3 Q9UGI6 1/20 0.41
GAA P10253 6/20 0.41
ALDH1A1 P00352 4/20 0.41
MAPT P10636 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
SLC2A1 P11166 1/20 0.41
CCR4 P51679 1/20 0.39
GCK P35557 2/20 0.39
AURKA O14965 1/20 0.39
GSK3B P49841 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL190565 0.91 RAB9A (0.46) KMT2ARAB9AMEN1NPC1CASP3
SCHEMBL190619 0.88 ALDH1A1 (0.47) KMT2ARAB9AMEN1NPC1CASP3
SCHEMBL190440 0.85 ALDH1A1 (0.42) KMT2ARAB9AMEN1NPC1CASP3
SCHEMBL190468 0.84 RAB9A (0.47) KMT2ARAB9AMEN1NPC1CASP3
SCHEMBL190971 0.84 KMT2A (0.46) KMT2ARAB9AMEN1NPC1CASP3
SCHEMBL190235 0.83 RAB9A (0.47) KMT2ARAB9AMEN1NPC1CASP3
SCHEMBL190666 0.83 CCR4 (0.54) KMT2ARAB9AMEN1NPC1CASP3
SCHEMBL190492 0.81 RAB9A (0.44) KMT2ARAB9AMEN1NPC1CASP3
SCHEMBL190400 0.81 RAB9A (0.55) KMT2ARAB9AMEN1NPC1CASP3
SCHEMBL190694 0.81 GCK (0.54) KMT2ARAB9AMEN1NPC1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1986645-B1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC (US) 2012-01-04 EP disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-8022222-B2 Glucokinase activators ARRAY BIOPHARMA, INC. (US) 2011-09-20 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
US-20090247526-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2009-10-01 US disclosed
CN-101437512-A Glucokinase activators ARRAY BIOPHARMA INC (US) 2009-05-20 CN disclosed
EP-1986645-A1 GLUCOKINASE ACTIVATORS Array Biopharma, Inc. (US) 2008-11-05 EP disclosed
WO-2007089512-A1 GLUCOKINASE ACTIVATORS ARRAY BIOPHARMA INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247526-A1 GLUCOKINASE ACTIVATORS GCKR, GCK, GALK1 KMT2A 2715/4885RAB9A 1808/4885MEN1 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.